Analytical aspects of molecular Alzheimer's disease biomarkers

• In general, a biomarker has multiple uses such as a diagnostic tool and a method to monitor therapy. The quality of a biomarker depends on how big the difference is between, for example, patients and healthy controls, but also on the capacity of the method used to measure it (the uncertainty in the method should be much less than the difference between the groups). A good biomarker should also be specific towards a disease, allowing for differentiation between clinically related syndromes. In addition, it is of importance that the stability of the methods used is high enough to establish cut-off levels both in individual laboratories and on a global scale. In the field of Alzheimer's disease, there are currently three cerebrospinal fluid markers that have been verified in multiple studies and the analytical aspects of measuring them will be discussed.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

accuracy

Alzheimer's disease

biomarkers

cerebrospinal fluid

pathophysiology

quality control

amyloid-beta peptides

cerebrospinal-fluid biomarkers

mild cognitive

impairment

tandem mass-spectrometry

phosphorylated tau

quantitative-analysis

csf biomarkers

protein

diagnosis

beta-amyloid((1-42))

baton m

1994

biochemical and biophysical research communications

v200

p1598

Publikations- och innehållstyp

ref (ämneskategori)

for (ämneskategori)